OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Live / Registered — Registered (as of 08 Aug 2023)
What this means for you
Registered since 08 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97342302
- Registration number
- 7130293
- Mark type
- Design + words
- Filed
- 01 Apr 2022
- Published for opposition
- 23 May 2023
- Registered
- 08 Aug 2023
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 08 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
- 02 Aug 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 02 Aug 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 02 Aug 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 23 May 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 May 2023 — PUBLISHED FOR OPPOSITION
- 03 May 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Apr 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Apr 2023 — EXAMINER'S AMENDMENT ENTERED
- 17 Apr 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 17 Apr 2023 — EXAMINERS AMENDMENT E-MAILED
- 17 Apr 2023 — EXAMINERS AMENDMENT -WRITTEN
- 14 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Apr 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE